Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial.

Revista:
Diabetes Obes Metab. 2011 Feb;13(2):137-43. doi: 10.1111/j.1463-1326.2010.01320.x.
Resumen:
Aim: Colesevelam is indicated to lower low density lipoprotein cholesterol (LDL-C) in hyperlipidaemia and improve glycaemic control in adults with type 2 diabetes. This short-term pilot study evaluates its effects in type 1 diabetes.
Artículo:
856
Patrocinado por Laboratorio NOVO NORDISK